LeMaitre Vascular, Inc. (LMAT) has a MoatMap StockRank of 86/100 based on Quality (76/100), Value (26/100), and Momentum (68/100) factor scores. The current signal is STRONG BUY. LeMaitre Vascular, a medical device company with a high quality score (Q:67) and strong moats from specialized devices, regulatory hurdles, and surgeon familiarity, fits the 'Durable Quality & Moats' criteria. However, its extremely low value score (V:17) indicates significant overvaluation, leaving no margin of safety and failing the Peter Lynch and Warren Buffett lenses. While a quality business, it lacks the powerful, unpriced macro tailwind that creates an asymmetric opportunity, and the current valuation removes any potential for outperformance from a 'reasonable price' perspective.
LeMaitre Vascular, Inc. is a global provider of medical devices for the treatment of peripheral vascular disease, designing, manufacturing, and marketing a broad portfolio of interventional and implantable devices. LeMaitre Vascular benefits from a comprehensive and specialized product portfolio addressing niche areas of peripheral vascular surgery, supported by a direct sales force. Its focus on innovative solutions for a specific disease state creates a strong competitive advantage.
| Price | $98.71 |
| Market Cap | $2.2B |
| P/E (TTM) | 36.29 |
| P/E (Forward) | 30.32 |
| Price/Book | 5.55 |
| Return on Equity | 16.5% |
| Return on Invested Capital | 13.9% |
| Debt/Equity | 46.68 |
| Gross Margin | 71.3% |
| Operating Margin | 26.7% |
| Revenue Growth | 11.2% |
| Dividend Yield | 1.0% |
| Free Cash Flow | $53M |
LeMaitre Vascular, Inc. operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).